loading
Trevi Therapeutics Inc stock is traded at $3.555, with a volume of 497.12K. It is down -5.45% in the last 24 hours and down -12.22% over the past month. Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
See More
Previous Close:
$3.76
Open:
$3.77
24h Volume:
497.12K
Relative Volume:
0.30
Market Cap:
$317.70M
Revenue:
-
Net Income/Loss:
$-29.07M
P/E Ratio:
-12.26
EPS:
-0.29
Net Cash Flow:
$-31.85M
1W Performance:
-9.54%
1M Performance:
-12.22%
6M Performance:
+27.88%
1Y Performance:
+163.33%
1-Day Range:
Value
$3.55
$3.81
1-Week Range:
Value
$3.55
$4.06
52-Week Range:
Value
$1.27
$4.68

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Name
Name
Trevi Therapeutics Inc
Name
Phone
203-304-2499
Name
Address
195 CHURCH STREET, NEW HAVEN, CT
Name
Employee
27
Name
Twitter
@TreviThera
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
TRVI's Discussions on Twitter

Compare TRVI with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TRVI
Trevi Therapeutics Inc
3.555 317.70M 0 -29.07M -31.85M -0.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-12-24 Reiterated H.C. Wainwright Buy
Sep-09-24 Resumed Leerink Partners Outperform
Aug-30-24 Initiated H.C. Wainwright Buy
Aug-30-24 Initiated Raymond James Outperform
Jun-13-24 Initiated Rodman & Renshaw Buy
Apr-12-23 Initiated B. Riley Securities Buy
Nov-22-22 Initiated SVB Leerink Outperform
Jun-03-19 Initiated BMO Capital Markets Outperform
Jun-03-19 Initiated Needham Buy
Jun-03-19 Initiated SVB Leerink Outperform
Jun-03-19 Initiated Stifel Buy
View All

Trevi Therapeutics Inc Stock (TRVI) Latest News

pulisher
Jan 20, 2025

Barclays PLC Acquires 61,317 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jan 20, 2025
pulisher
Jan 17, 2025

Short Interest in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Decreases By 17.0% - MarketBeat

Jan 17, 2025
pulisher
Jan 15, 2025

Jane Street Group LLC Sells 33,439 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jan 15, 2025
pulisher
Jan 11, 2025

Trevi Therapeutics’ (TRVI) “Buy” Rating Reiterated at D. Boral Capital - Defense World

Jan 11, 2025
pulisher
Jan 09, 2025

Trevi Therapeutics’ $50 Million Common Stock Offering - Global Legal Chronicle

Jan 09, 2025
pulisher
Jan 08, 2025

Trevi Therapeutics stock target lifted, holds Buy on treatment progress By Investing.com - Investing.com Canada

Jan 08, 2025
pulisher
Jan 08, 2025

What Makes Trevi Therapeutics (TRVI) a New Buy Stock - Yahoo Finance

Jan 08, 2025
pulisher
Jan 08, 2025

Trevi Therapeutics (NASDAQ:TRVI) Receives "Buy" Rating from D. Boral Capital - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference - Nasdaq

Jan 08, 2025
pulisher
Jan 08, 2025

Trevi Therapeutics (TRVI) Stock Price, News & Analysis - MarketBeat

Jan 08, 2025
pulisher
Jan 07, 2025

Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - GuruFocus.com

Jan 07, 2025
pulisher
Jan 06, 2025

Geode Capital Management LLC Increases Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - MarketBeat

Jan 06, 2025
pulisher
Jan 06, 2025

Geode Capital Management LLC Has $4.22 Million Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jan 06, 2025
pulisher
Jan 05, 2025

Barclays PLC Raises Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jan 05, 2025
pulisher
Jan 05, 2025

Analysts Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $9.31 - Defense World

Jan 05, 2025
pulisher
Jan 04, 2025

Trevi Therapeutics stock soars to 52-week high of $4.68 By Investing.com - Investing.com Australia

Jan 04, 2025
pulisher
Jan 03, 2025

Trevi Therapeutics stock soars to 52-week high of $4.68 - Investing.com India

Jan 03, 2025
pulisher
Jan 02, 2025

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a - GuruFocus.com

Jan 02, 2025
pulisher
Jan 02, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Jan 02, 2025
pulisher
Dec 31, 2024

State Street Corp Has $3.18 Million Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Dec 31, 2024
pulisher
Dec 26, 2024

Retail Chatter For Trevi Therapeutics Soars After Enrollment Target For Chronic Cough Study Hits 75% - MSN

Dec 26, 2024
pulisher
Dec 26, 2024

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Sees Large Increase in Short Interest - MarketBeat

Dec 26, 2024
pulisher
Dec 25, 2024

Trevi Therapeutics Reports Second Quarter 2024 Financial Results - GuruFocus.com

Dec 25, 2024
pulisher
Dec 20, 2024

BNP Paribas Financial Markets Purchases 6,764 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Dec 20, 2024
pulisher
Dec 19, 2024

Cough in Idiopathic Pulmonary Pipeline Report 2024: Clinical Trials Progress and Therapies by DelveInsight | Algernon Pharma, Seyltx, Melius Pharma, NeRRe Therapeutics, Trevi Therapeutics - Barchart

Dec 19, 2024
pulisher
Dec 19, 2024

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 - The Eastern Progress Online

Dec 19, 2024
pulisher
Dec 16, 2024

Trevi Therapeutics sets $50 million stock offering price By Investing.com - Investing.com Australia

Dec 16, 2024
pulisher
Dec 16, 2024

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 - The Eastern Progress Online

Dec 16, 2024
pulisher
Dec 16, 2024

Form 424B5 Trevi Therapeutics, Inc. - StreetInsider.com

Dec 16, 2024
pulisher
Dec 16, 2024

Trevi Therapeutics Prices of $50 Million Underwritten Offering - citybiz

Dec 16, 2024
pulisher
Dec 16, 2024

Trevi Therapeutics sets $50 million stock offering price - Investing.com

Dec 16, 2024
pulisher
Dec 16, 2024

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering - PR Newswire

Dec 16, 2024
pulisher
Dec 15, 2024

Trevi Therapeutics’ (TRVI) “Buy” Rating Reiterated at Needham & Company LLC - Defense World

Dec 15, 2024
pulisher
Dec 15, 2024

Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $7.50 - Defense World

Dec 15, 2024
pulisher
Dec 13, 2024

Trevi Therapeutics (TRVI) Gains Market Traction After Positive Trial Results - Stocks Telegraph

Dec 13, 2024
pulisher
Dec 13, 2024

Institutional investors control 39% of Trevi Therapeutics, Inc. (NASDAQ:TRVI) and were rewarded last week after stock increased 38% - Simply Wall St

Dec 13, 2024
pulisher
Dec 12, 2024

Trevi stock rockets on Haduvio study update - MSN

Dec 12, 2024
pulisher
Dec 12, 2024

Trevi stock rockets on Haduvio study update (TRVI:NASDAQ) - Seeking Alpha

Dec 12, 2024
pulisher
Dec 12, 2024

Trevi Therapeutics stock soars to 52-week high of $4.07 - Investing.com

Dec 12, 2024
pulisher
Dec 12, 2024

Trevi Therapeutics Shares Hit 52-Week High After Positive Trial Analysis - MarketWatch

Dec 12, 2024
pulisher
Dec 12, 2024

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday? - Benzinga

Dec 12, 2024
pulisher
Dec 12, 2024

Trevi Therapeutics, Inc. Announces Positive Outcome from Sample Size Re-Estimation Resulting in No Change to the Current Sample Size for the Phase 2B Coral Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough - Marketscreener.com

Dec 12, 2024
pulisher
Dec 12, 2024

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough - PR Newswire

Dec 12, 2024
pulisher
Dec 12, 2024

Nasdaq Down 50 Points; US Initial Jobless Claims Rise - Benzinga

Dec 12, 2024
pulisher
Dec 12, 2024

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences - The Eastern Progress Online

Dec 12, 2024
pulisher
Dec 11, 2024

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $9.13 Consensus Target Price from Brokerages - Defense World

Dec 11, 2024
pulisher
Dec 10, 2024

Trevi Therapeutics to Participate in September Investor and Medical Conferences - The Eastern Progress Online

Dec 10, 2024
pulisher
Dec 09, 2024

HC Wainwright Has Negative Outlook of TRVI FY2024 Earnings - MarketBeat

Dec 09, 2024

Trevi Therapeutics Inc Stock (TRVI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
Cap:     |  Volume (24h):